Navigation Links
International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk
Date:5/27/2008

CAMBRIDGE, United Kingdom, May 27 /PRNewswire-USNewswire/ -- The Biomedical Excellence for Safer Transfusion (BEST) Collaborative will be presenting its concerns regarding the scientific validity and medical implications of several recent papers purporting to show that transfusion of older units of Red Blood Cells leads to greater risk. The organization will highlight its position during the U.S. Department of Health and Human Services (HHS) meeting of the Advisory Committee on Blood Safety and Availability (ACBSA) on May 30, 2008, at the Hilton Rockville Hotel, in Rockville, Md.

The BEST Collaborative is an international research organization that works collaboratively to explore ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy. The position of BEST will be presented by Larry Dumont, PhD, Assistant Professor of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; and co-leader of BEST's Clinical Studies Team.

"Several retrospective studies have suggested a correlation between transfusion of older Red Blood Cells and poorer outcomes in certain clinical settings," said Dr. Dumont. "Such studies display several important shortcomings in their assumptions, designs and reporting."

In particular, the BEST Collaborative comments will focus on the recent New England Journal of Medicine article written by Colleen Gorman Koch, MD, and colleagues, noting the study had several key inadequacies, including:

1. The groups receiving units of different storage periods appeared not at all comparable.

The groups differed in many important clinical features, including the frequency of left ventricular dysfunction, prior myocardial infarction, mitral valve regurgitation, body size, severity of heart disease, and the presence of peripheral vascular disease. These suggest that the patient groups were not similar and may have come to surgery in very different situations making a comparison of their outcomes meaningless.

The groups displayed a skewed distribution of ABO groups and, furthermore, had an even more skewed distribution of ABO groups among the Red Blood Cells units transfused. This also suggests lack of comparability between the groups and in their clinical situations.

2. The survival curve shown in the paper was not adjusted for the many differences between the groups.

Correction of results for confounding factors such as blood type, number of transfusions, and so forth would have been a legitimate and critical step in the analysis, but this was not performed for the results that were illustrated, and sufficient details of the analyses have not been provided to allow readers to judge the appropriateness of the analyses actually performed.

Uncorrected survival curves present misleading pictures of the potential impact of red cell units' storage time. Presentation of stratified analyses should have been considered.

3. Storage age was treated as a dichotomous variable (i.e., "young" vs. "old") rather than investigating the association of increasing age with changing outcome.

4. No plausible mechanism explains the divergence of survival curves long after the natural removal of the transfused red cells at the end of their lifespan.

5. Most important is the indication that patients receiving older units of blood received more units of blood.

The number of transfusions required by a recipient has been shown to correlate with outcome, but this association was not properly accounted for. Applying data published from this same research group, all the "excess mortality" they associated with the transfusion of older red cells can be attributed directly to the patients who received older units having received slightly more units of blood.

According to the BEST Collaborative, other studies using the more direct and powerful approach of prospective assignment of subjects to "younger" vs. "older" units of Red Blood Cells have not supported the contention of recent papers that older units convey significantly higher risk. These studies have used a variety of relevant physiologic endpoints.

"The only way to address the weaknesses of recent retrospective, epidemiologic studies is to properly design and execute a prospective randomized clinical trial with a clear, clinically relevant endpoint that is sufficiently powered to address the question," said Dr. Dumont. "The pathophysiology of the effects of red cell storage time on patient outcomes is not understood, and funding initiatives, such as the recent one announced by the National Heart, Lung and Blood Institute, should be expanded."

Overall, the BEST Collaborative finds the methodology of the Koch study inadequate to change transfusion policy. The organization encourages analyses of other data, particularly from randomized trials representing comparable groups of patients.

To learn more about the BEST Collaborative, visit: http://www.bestcollaborative.org.


'/>"/>
SOURCE Biomedical Excellence for Safer Transfusion (BEST)Collaborative
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Family Health International Featured at Global Health Council Conference
2. International Training and Development Company, Landmark Education, Mischaracterized as Religion
3. Lockheed Martin Completes Acquisition of Eagle Group International, LLC
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington
6. Murad, Inc., Appoints Fernando Braga, Jr. as Director of International Business for Latin America
7. Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China
8. China Yingxia International, Inc. Reports First Quarter 2008 Results
9. Animal behavior turned into robots and more at 4th international AMAM symposium
10. International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam
11. Service Corporation International Declares Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Routine ... measurements are consistently correct. However, regular performance testing is often neglected because ... a solution: SmartCal™ . This innovative test substance offers a fast ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Johnson & Weaver, LLP announces that a class ... Biomet Holdings, Inc. (NYSE: ZBH )  securities during ... (the "Class Period"). Zimmer Biomet provides musculoskeletal healthcare ... products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016 Sickle ... by rigid, sickle-shaped red blood cells that get stuck ... severe pain, stroke, organ failure, and complications leading to ... are born with SCD, and most of them lack ... fact, the only established long-term therapy for SCD, a ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: